AMLN Related Rumors
-
Jefferies Says FDA Request from Amylin (AMLN) Will Not Impact Acquisition Potential
-
Amylin (AMLN) Wants a Buyout Price At Least in the Low-to-Mid $30s - Jefferies
-
Amylin (AMLN) Bidding Intensifies; Sale Expected in July
-
Shares of Amylin (AMLN) on the move as Reuters reporting first round bids over $25/share
-
Amylin Pharmaceuticals (AMLN) Sees Late Day Pressure
-
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
-
Amylin (AMLN) Attracting a Host of Other Suitors, Shares Rise
-
Amarin (AMRN) Shares Rise Following M&A Chatter; Other Targets Mentioned (AMLN) (FRX)
-
Amylin (AMLN) Shares Rally Into Close as WSJ Says Bristol (BMY) Still Looking at Co.
-
Baird Comments on Amylin (AMLN) On Takeover Speculation
-
UPDATE: Amylin (AMLN) Rejected $22/Share Bid from Bristol-Myers (BMY)
-
Amylin (AMLN) Won't Comment on Takeover Reports
-
Amylin (AMLN) Shares Surge 50+% Amid Rumor Co. Rejected $3.5B Bid from Bristol (BMY)
-
Amylin (AMLN) said to have rejected a $3.5B bid from Bristol-Myers (BMY) -Bloomberg
-
Biotech Stocks Could See Action On Valeant (VRX) Bid for Cephalon (CEPH): (BIIB) (JAZZ) (DNDN) (REGN) (more...)
-
This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
-
Deutsche Bank Maintains a 'Buy' on Amylin Pharmaceuticals (AMLN); Thinking Long-Term: Bydureon a Likely Blockbuster
-
Wall Street Hubbub 9/22: The Ivy League Football "Mafia", Brocade Surges On Takeover Talk, Netezza Jumps On Talk of Higher Bid
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Merriman Curhan Ford Initiates Coverage on Amylin Pharmaceuticals (AMLN) with a Buy
-
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
-
Biotech Rumor Mill Hopping After Hostile Bid for OSI Pharmaceuticals (OSIP)
-
Amylin Pharmaceuticals (AMLN) Sees Upside Action
-
Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)
-
Amylin (AMLN) Has Lost At Least 2 Board Seats in Battle with Icahn -CNBC
-
Amylin (AMLN) Agrees With Carl Icahn Affiliates, Eastbourne on Talks -Bloomberg
-
Icahn Wouldn't Recommend Selling Amylin (AMLN) for Less Than $30/Sh - Dow Jones
-
Amylin (AMLN) Has Investors Fired-Up for Change
-
Like ImClone, Icahn Will Get Amylin (AMLN) Sold
-
Eastbourne Capital May Talk With Amylin Pharma (AMLN) About A Possible Sale
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid
-
Carl Icahn files 13D on Amylin (AMLN), boosts stake to 6.5%. Seeks talks
-
StreetInsider.com Market Rumors 07/12
-
AMLN Higher on LLY Takeover Chatter
-
AMLN Higher on Takeover Chatter
-
AMLN and LLY Wins FDA Approval for BYETTA (exenatide)
-
Traders Eyeing AMLN Ahead of FDA Ruling on Exenatide
Back to AMLN Stock Lookup
